The four pillars of our Commitment
Respecting and understanding the patient community perspective
Expanding access to our medicines
Conducting responsible clinical trials
Recognizing the importance of transparency and reporting
We recognize the importance of patients and caregivers understanding what they can expect from Novartis.
in general medicines obtained patient insights before first-in-human trials (healthy volunteers). Piloted patient panels for five Proof of Concept indications
94% requests approved for 64 compounds in 82 countries - providing pre-approval access to Novartis medicines
comprising 69 clinical trials, had a patient engagement component to obtain the patient perspective on the design and / or conduct of clinical trials
included Patient Reported Outcomes (PRO) conducted in 57 countries
from Phase 1-4 clinical trials sent to investigators to share with 14,668 trial participants and posted on novartisclinicaltrials.com
reached through Access programs
Clinical trials are scientific studies conducted to find better ways to prevent, screen for, diagnose or treat disease.
Novartis is currently conducting clinical trials around the world for a number of diseases.
Novartis Managed Access makes investigational or unapproved treatments available to eligible patients with serious or life-threatening diseases. Your physician may request access.
Diversity in clinical trials is integral to who we are at Novartis and we are working hard to improve both the diversity of patients enrolled in our clinical research and the investigators involved in our trials. (PDF 0.2 MB)
Global Oncology Patient Insights Panels (GOPIPs) are giving patients and advocates a critical voice in advancing lung cancer trials.
For questions about Novartis, medical inquiries about our products and/or information about services, we recommend you contact the Novartis office in your country. If you’re seeking a global list of products, visit our Global Product Portfolio.